NOVOB80 Stock Price and Chart — SET:NOVOB80

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk had a positive quarter with FDA drug shortage initiatives and NovoCare launch, but prescription growth was below expectations. Barclays adjusted FY25 sales growth forecast to +19%.

Novo Nordisk's Rybelsus, an oral diabetes drug, showed a 14% lower risk of heart-related death and a 26% reduction in non-fatal heart attacks in a trial with 9,650 patients.

Hims & Hers Health will sell generics of Novo Nordisk's diabetes drug liraglutide, alongside Wegovy and Eli Lilly's Zepbound, on its telehealth platform.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.